Treatment Strategies in Endogenous Fungal Endophthalmitis - Takeaways - MDSpire

Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

  • By

  • Arthi Venkat, MD, MS

  • Eleanor M. Burton, MD

  • January 1, 2026

  • 7 min

Share

  • 1

    Endogenous fungal endophthalmitis accounts for 5% to 10% of endophthalmitis cases, with fungi and bacteria each representing about half.

  • 2

    Primary risk factors for endogenous fungal endophthalmitis include malignancy, intravenous drug use, and immunosuppression.

  • 3

    The 2016 IDSA guidelines recommend systemic fluconazole or voriconazole for all patients, with adjunctive intravitreal antifungals for severe cases.

  • 4

    In a multicenter study, 72% of eyes received combination systemic and intravitreal antifungals, with voriconazole and fluconazole being the most common agents.

  • 5

    Treatment strategies for endogenous fungal endophthalmitis vary regionally, with systemic culture positivity influencing the choice of initial therapy.

Original Source(s)

Treatment Strategies in Endogenous Fungal Endophthalmitis

  • by Arthi Venkat, MD, MS, Eleanor M. Burton, MD

  • January 1, 2026

Related Content

Uveitis and Inflammation: A Two-Way Risk

New study explores the bi-directional relationship between uveitis and autoimmune & inflammatory diseases

  • February 5, 2026

  • 2 min
Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

Herpetic Eye Disease Is Not a Single Event

Joseph P. Shovlin, OD, FAAO, reviewed diagnosis, management, and emerging evidence related to chronic herpetic eye disease prevention at Optometry's Meeting 2026.